{"id":"NCT02494583","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","officialTitle":"A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-31","primaryCompletion":"2019-03-26","completion":"2022-06-06","firstPosted":"2015-07-10","resultsPosted":"2020-03-13","lastUpdate":"2023-04-13"},"enrollment":763,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Adenocarcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"5-FU","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pembrolizumab Monotherapy (Pembro Mono)","type":"EXPERIMENTAL"},{"label":"Pembrolizumab + SOC Chemotherapy (Pembro Combo)","type":"EXPERIMENTAL"},{"label":"Placebo + SOC Chemotherapy (SOC)","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Participants whose tumors express programmed death-ligand 1 (PD-L1) will be randomly assigned to one of the three treatment arms of the study: pembrolizumab as monotherapy \\[pembro mono\\], pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin plus 5-fluorouracil (5-FU) or capecitabine \\[pembro combo\\], or placebo plus SOC chemotherapy with cisplatin plus 5-fluorouracil (5-FU) or capecitabine \\[SOC\\].\n\nThe primary study hypotheses are that pembrolizumab in combination with SOC chemotherapy is superior to SOC chemotherapy alone in terms of Progression-free Survival (PFS) and Overall Survival (OS) in participants with PD-L1 Combined Positive Score (CPS) ≥1, pembrolizumab in combination with SOC chemotherapy is superior to SOC chemotherapy alone in terms of OS in participants with PD-L1 CPS ≥10, pembrolizumab monotherapy is non-inferior to SOC chemotherapy alone in terms of OS in participants with PD-L1 CPS ≥1, and pembrolizumab monotherapy is superior to SOC chemotherapy alone in terms of OS in participants with PD-L1 CPS ≥1 and in participants with PD-L1 CPS ≥10.","primaryOutcome":{"measure":"Pembro Combo vs SOC: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With PD-L1 CPS ≥1 (All Participants)","timeFrame":"Up to approximately 36 months","effectByArm":[{"arm":"Pembrolizumab + SOC Chemotherapy (Pembro Combo)","deltaMin":6.9,"sd":null},{"arm":"Placebo + SOC Chemotherapy (SOC)","deltaMin":6.4,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.03918"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["40117530","37037952","36533429","35657979","33792646","32880601"],"seeAlso":["http://merckoncologyclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":93,"n":254},"commonTop":["Nausea","Anaemia","Decreased appetite","Fatigue","Vomiting"]}}